恒瑞医药SHR-2173、HRS-5632两项创新药临床试验获批开展

参考文献：

1.Zufferey, A.; Kapur, R.; Semple, J. W. Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP). J. Clin. Med. 2017, 6 (2), 16. https://doi.org/10.3390/jcm6020016.

2.Shrestha, S.; Nazy, I.; Smith, J. W.; Kelton, J. G.; Arnold, D. M. Platelet Autoantibodies in the Bone Marrow of Patients with Immune Thrombocytopenia. Blood Adv. 2020, 4 (13), 2962–2966. https://doi.org/10.1182/bloodadvances.2020001846

3.Lee, J. Y.; Lee, J.-H.; Lee, H.; Kang, B.; Kim, J.-W.; Kim, S. H.; Lee, J.-O.; Kim, J. W.; Kim, Y. J.; Lee, K.-W.; Kim, J. H.; Choi, H. S.; Lee, J. S.; Bang, S.-M. Epidemiology and Management of Primary Immune Thrombocytopenia: A Nationwide Population-Based Study in Korea. Thromb. Res. 2017, 155, 86–91. https://doi.org/10.1016/j.thromres.2017.05.010.

4.Moulis, G.; Palmaro, A.; Montastruc, J.-L.; Godeau, B.; Lapeyre-Mestre, M.; Sailler, L. Epidemiology of Incident Immune Thrombocytopenia: A Nationwide Population-Based Study in France. Blood 2014, 124 (22), 3308–3315. https://doi.org/10.1182/blood-2014-05-578336.

5.中国血脂管理指南修订联合专家委员会. 中国血脂管理指南（2023年）[J]. 中华心血管病杂志, 2023, 51(3):221‐255.